Type 2 diabetes reduces life expectancy by up to 10 years and around half of all patients die from cardiovascular disease (CVD). NICE advises that in patients whose QRISK2 score is 10% or higher and those with established CVD, an SGLT2 inhibitor should be used early on. For those patients initially assessed as not having established CVD or a QRISK2 score of 10% or higher, at each assessment two factors should be considered: if the HbA_1c target has been achieved and whether their CVD risk has changed.